Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquisition, in-licensing, out-licensing, manufacturing, marketing and distribution of pharmaceutical products, consumer health products and medical devices. It finances other life sciences companies and secures product distribution rights for Canada and select international markets with over 150 products. The Company monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.